ArticleInternational journal of nanomedicine2021
Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment.
Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Membrane-anchored DNA nanodevice with allosteric aptamer arms enables parallel probing and on-site drug delivery.Nature communications · 2026Article
- Extracellular Vesicle-Mediated Nucleolin Transfer in Glioblastoma: A Targetable Axis Driving Blood-Tumour Barrier Formation.Journal of extracellular vesicles · 2026Article
- AS1411-Bivalent-Cholesterol-Anchor Equipped with Zinc Phthalocya-Nine Enables NK Cells Derived Exosomes to Realize Effective Tumor-Tropism Photodynamic Therapy.Pharmaceutics · 2026Article
- Chemically Cross-Linked Nanocapsules from Terpolymers of Polyethylene Glycol-Polylactide with Cationic Pendent Groups for Pgp-siRNA and Doxorubicin Codelivery in Overcoming Multidrug Resistance in Breast Cancer.Molecular pharmaceutics · 2026Article
- Porous PLGA microspheres for the inhalation delivery of icariin and miR-23b in the treatment of metastatic lung cancer.Asian journal of pharmaceutical sciences · 2025Article
- Aptamer-functionalized nanomaterials (AFNs) for therapeutic management of hepatocellular carcinoma.Journal of nanobiotechnology · 2024Review
- miRNAs as short non-coding RNAs in regulating doxorubicin resistance.Journal of cell communication and signaling · 2023Review
- Smart nanoparticles for cancer therapy.Signal transduction and targeted therapy · 2023Review
- Selective Delivery to Cardiac Muscle Cells Using Cell-Specific Aptamers.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Polymeric-Micelle-Based Delivery Systems for Nucleic Acids.Pharmaceutics · 2023Review
- DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors.Cancers · 2023Review
- Codelivery of TGF-β1 and anti-miR-141 by PLGA microspheres inhibits progression of intervertebral disc degeneration.Journal of orthopaedic surgery and research · 2023Article
- Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets.Frontiers in endocrinology · 2023Article
- Application of aptamer functionalized nanomaterials in targeting therapeutics of typical tumors.Frontiers in bioengineering and biotechnology · 2023Review
- Aptamer-engineered (nano)materials for theranostic applications.Theranostics · 2023Review
- The Impact of PEGylation on Cellular Uptake and In Vivo Biodistribution of Gold Nanoparticle MRI Contrast Agents.Bioengineering (Basel, Switzerland) · 2022Article
- Broad-Spectrum Theranostics and Biomedical Application of Functionalized Nanomaterials.Polymers · 2022Review
- A peptide-DNA hybrid bio-nanomicelle and its application for detection of caspase-3 activity.Frontiers in chemistry · 2022Article
- The emerging role of exosomes in innate immunity, diagnosis and therapy.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug resistance (MDR) has emerged to be a major hindrance in cancer therapy, which contributes to the reduced sensitivity of cancer cells toward chemotherapeutic drugs mainly owing to the over-expression of drug efflux transporters. The combination of gene therapy and chemotherapy has been considered as a potential approach to improve the anti-cancer efficacy by reversing the MDR effect. MATERIALS AND
methodsThe AS1411 aptamer-functionalized micelles were constructed through an emulsion/solvent evaporation strategy for the simultaneous co-delivery of doxorubicin and miR-519c. The therapeutic efficacy and related mechanism of micelles were explored based on the in vitro and in vivo active targeting ability and the suppression of MDR, using hepatocellular carcinoma cell line HepG2 as a model.
resultsThe micelle was demonstrated to possess favorable cellular uptake and tumor penetration ability by specifically recognizing the nucleolin in an AS1411 aptamer-dependent manner. Further, the intracellular accumulation of doxorubicin was significantly improved due to the suppression of ABCG2-mediated drug efflux by miR-519c, resulting in the efficient inhibition of tumor growth.
conclusionThe micelle-mediated co-delivery of doxorubicin and miR-519c provided a promising strategy to obtain ideal anti-cancer efficacy through the active targeting function and the reversion of MDR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.